NAS:MOR (Germany)  
MorphoSys AG logo

MorphoSys AG

$ 5.02 +0.07 (+1.41%) 02:03 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 685.93M
Enterprise V:
$ 251.24M
Volume:
30.95K
Avg Vol (2M):
215.72K
Also Trade In:
Volume:
30.95K
Market Cap $:
685.93M
PE Ratio:
At Loss
Avg Vol (2-Month):
215.72K
Enterprise Value $:
251.24M
PB Ratio:
0

Business Description

Description
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Name Current Vs Industry Vs History
Cash-To-Debt 2.19
Equity-to-Asset -0.01
Debt-to-Equity -12.09
Debt-to-EBITDA -0.66
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.7
Distress
Grey
Safe
Beneish M-Score -1.39
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 71.51
9-Day RSI 71.38
14-Day RSI 67.28
6-1 Month Momentum % -35.5
12-1 Month Momentum % -55.36

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.98
Quick Ratio 2.91
Cash Ratio 2.29
Days Inventory 158.64
Days Sales Outstanding 130.1
Days Payable 630.3

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.7